Chronic Calcium Antagonist Use in Carcinoma of the Lung and Colon: A Retrospective Cohort Observational Study

References

• Yoneda T, Kitamura M, Ogawa T, et al. Control of VX2 carcinoma cell growth in culture by calcium, calmodulin and prostaglandins. Cancer Res 1985; 45: 396–405
   Google Scholar
• Myers C, Cowan K, Sinha B, . The phenomenon of pleiotropic drug resistance. Important Advances in Oncology, V DeVita, S Rosenberg, S Hellman, et al. Lippincott, Philadelphia 1987; 27–38
   Google Scholar
• Ozols R F, Cowan K. New aspects of clinical drug resistance: The role of gene amplification and the reversal of resistance in drug refractory cancer. Important Advances in Oncology, V DeVita, S Rosenberg, S Hellman. Lippincott, Philadelphia 1987; 129–157
   Google Scholar
• Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316: 1388–1393
   PubMed Web of Science ®Google Scholar
• Kessel D. Circumvention of resistance to anthracyclines by calcium antagonists and other membrane-perturbing agents. Cancer Surv 1986; 5: 109–127
   PubMedGoogle Scholar
• Start G R. Cancer chemotherapy. Progress in understanding multidrug resistance. Nature 1986; 324: 407–408
   PubMed Web of Science ®Google Scholar
• Onoda J M, Diglio C, Taylor J D, et al. Antimetastatic effect of the calcium channel blocker dilantizem (abstr). Proc Ann Meet Am Assoc Cancer Res 1984; 25: 351
   Web of Science ®Google Scholar
• Honn K V, Onoda J M, Diglio C A, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis 1984; 2: 61–77
   PubMed Web of Science ®Google Scholar
• Onoda J M, Sloan B F, Taylor J D, . Calcium channel blockers: inhibitors of tumor cell-platelet-endothelial cell interactions. Hemostatic Mechanisms and Metastases, K V Honn, B F Sloane, et al. Martinus Nijhoff, Boston 1984; 244–258
   Google Scholar
• Honn K V, Onoda J M, Diglio C A, et al. Calcium channel blockers: potential antimetastatic agents. Proc Soc Exp Biol Med 1983; 174(1)16–19
   PubMed Web of Science ®Google Scholar
• Bando H, Yamashita T, Tsubura E. Effects of antiplatelet agents on pulmonary metastases. Gann 1984; 75(3)284–291
   PubMedGoogle Scholar
• Gastpar H, Ambrus J L, Ambrus C M. Platelet aggregation inhibitors in the prevention of metastasis in neoplastic disease: a review of experimental and clinical investigations. J Med 1981; 12: 15–33
   PubMedGoogle Scholar
• Tsuruo T, Iida H, Makishima F, et al. Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil. Cancer Chemother Pharmacol 1985; 14: 30–33
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Nojiri M, et al. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983; 43(6)2905–2910
   PubMed Web of Science ®Google Scholar
• Slater L M, Murray S L, Wetzel M W, et al. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest 1982; 70(5)1131–1134
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Nasanuma K, et al. Promotion of verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res 1983; 43(2)808–813
   PubMed Web of Science ®Google Scholar
• Slater L, Murray S, Wetzel M, et al. Verapamil potentiation of VP-16–213 in acute lymphatic leukemia (ALL) in vivo and reversal of pleiotropic drug resistance (PDR). Proc Am Assoc Cancer Res 1985; 26: 336
   Web of Science ®Google Scholar
• Onoda J M, Jacobs J R, Taylor J D, et al. Cisplatinum and nifedipine: synergistic cytotoxicity against murine solid tumors and their metastases. Cancer Lett 1986; 30: 181–188
   PubMed Web of Science ®Google Scholar
• Ozols R F, Rogan A M, Hamilton T C, et al. Verapamil (V) plus adriamycin (ADR) in refractory ovarian cancer (OC): design of a clinical trial on basis of reversal of ADR resistance (R) in human OC cell lines (CL). Proc Ann Meet Am Assoc Cancer Res 1984; 25: 300
   Web of Science ®Google Scholar
• Benson A B, III, Koeller J M, Trump D C, et al. A phase I study and pharmacokinetics of vinblastine (VBL) and verapamil (VPL) given by concurrent intravenous infusion (abstr). Proc Ann Meet Am Assoc Cancer Res 1984; 25: 162
   Web of Science ®Google Scholar
• Cantwell B, Buamah P, Harris A L. Phase I and II study of oral verapamil (VRP) and intravenous vindesine (VDN). Proc Am Assoc Cancer Res 1985; 26: 218
   Google Scholar
• Mannel R G, Stone M, Morice E. A pilot study of verapamil plus FOM in the treatment of non-small cell lung cancer. Proc Am Soc Clin Oncol 1985; 4: 188
   Google Scholar
• Hait W N, Lazo J S, Chen D-L, et al. Pre-clinical and phase I-II studies of bleomycin (BLEO) with calmodulin-antagonists (CaM-A). Proc Am Assoc Cancer Res 1985; 26: 326
   Web of Science ®Google Scholar
• Present C A, Kennedy P S, Wiseman C, et al. Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 1986; 9: 355–357
   PubMed Web of Science ®Google Scholar
• Bessho F, Kinumake H, Kobayashi M, et al. Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem. Med Pediatr Oncol 1985; 18: 199–202
   Google Scholar
• Dalmark M, Pals H. Phase II trial of doxorubicin (DOX) in combination with verapamil (VRP) in the treatment of advanced colorectal cancer. Proc 4th Europ Conf Clin Oncol, Madrid, Nov, 1–41987, 43
   Google Scholar
• Jirillo A, DeMicheli R, Bonciarelli G, et al. 4′Epidoxorubicin (E) pus verapamil (V) in anthracycline (A) pretreated cancer patients. Proc 4th Europ Conf Clin Oncol Madrid. Nov, 1–41987, 81
   Google Scholar
• Pujade-Lauraine E, Darse T, Cleophax J P, et al. Continuous prolonged 5-fluorouracil infusion vindesine and verapamil (WF): a highly effective combination in multiresisant metastastic breast cancer (MBC). Proc 4th Europ Conf Clin Oncol, Madrid, Nov, 1–41987, 115
   Google Scholar
• Taniguchi H, Murakami K, Morita S, et al. Calcium antagonist (Dillitiazem) for reversal of hypoglycemic symptoms in insulinoma. Lancet 1977; 2(8036)501
   PubMed Web of Science ®Google Scholar
• Serfas D, Shoback D M, Lorell B H. Phaeochromocytoma and hypertropic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade. Lancet 1983; 2(8352)711–713
   PubMed Web of Science ®Google Scholar
• Ahlman H, Nilsson O, Gronstad K-O, et al. Verapamil and diarrhea in the carcinoid syndrome—clinical and experimental observations on serotonin release. Br J Cancer 1986; 54: 251–256
   PubMed Web of Science ®Google Scholar
• Zacharski L R, Moritz T E. Effect of RA-233 (mopidamole) on surival in carcinoma of the lung and colon. Final Report of VA Cooperative Study #188. Thrombos Haemostas 1987; 58: 508
   Web of Science ®Google Scholar
• Zacharski L R, Moritz T E, Baczek L A, et al. Effect of RA-233 (mopidamole) in survival in carcinoma of the lung and colon. Final Report of VA Cooperative Study #188. J Natl Cancer Inst 1988; 80(2)90–97
   PubMed Web of Science ®Google Scholar
• Zacharski L R, Henderson W G, Riddes F, et al. Platelets and malignancy: rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. AM J Clin Oncol 1982; 5: 593–609
   PubMed Web of Science ®Google Scholar
• Gehan E A. A generalized Wilcoxan test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203–223
   PubMed Web of Science ®Google Scholar
• Cox D R. Regression models and life tables. J R Stat Soc (Series B) 1972; 34: 187–220
   Web of Science ®Google Scholar
• Cochran W G. Sampling Techniques, 3rd ed. Wiley, New York 1977
   Google Scholar
• Henderson W G, Zacharski L R, Spiegel, et al. Comparison of local vs central tumor measurements in a multicenter cancer trial. Am J Clin Oncol 1984; 7(6)705–712
   PubMed Web of Science ®Google Scholar
• Myers A K, Ramwell P W. Comparison of nifedipine and verapamil in thrombosis models. Clin Res 1984; 32: 316
   Google Scholar
• Pumphrey C W, Foster V, Dewanjee M K, et al. A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs. Throm Res 1982; 28: 663–675
   PubMed Web of Science ®Google Scholar
• Pumphrey C W, Fuster V, Dewanjee M K, et al. Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. Am J Cardiol 1982; 51: 591–605
   Web of Science ®Google Scholar
• Dewanjee M K, Pumphrey C W, Murphy K P, et al. Evaluation of platelet-inhibitor drugs in a canine bilateral femoral graft implant model. Trans Am Soc Artif Intern Organs 1982; 28: 504–509
   PubMedGoogle Scholar
• Ann Y S, Jy W., Chua L, et al. Calcium channel blockade for thrombosis and other disorders. Clin Res 1984; 32: 494
   Google Scholar
• Schroder I, Kostering H, Grone J H, et al. Langzesttuntersuchungen der blutgerinnung und fibinolyse bei patienten unter antihypetensiver therapie (captopril, nifedipin, und metripranolol + butazid). Nieren Hochdruck 1982; 11: 209
   Google Scholar
• Fine R L, Koizumi S, Curt G A, et al. Verapamil (VP) does not enhance anticancer drug toxicity for human marrow myeloid-macrophage colony-forming units (CFU-GM) (meeting abstract). Proc Ann Meet Am Soc Clin Oncol 1984; 3: 40
   Google Scholar
• Fine R L, Koizumi S, Curt G A, et al. Effect of calcium channel blockers on human CFU—CM cytotoxic drugs. J Clin Oncol 1987; 5: 489–495
   PubMed Web of Science ®Google Scholar
• Ozols R F, Cunnion R E, Klecker R W, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641–647
   PubMed Web of Science ®Google Scholar